Table 2 Tumoral + TIM-3 (≥1%) by grade and mismatch repair status, n/N (%)

From: TIM-3 in endometrial carcinomas: an immunotherapeutic target expressed by mismatch repair-deficient and intact cancers

 

MMR-Intact

nm-MMRd

MLH1-hm

Total

Low-grade (FIGO 1 endometrioid)

5/9 (56%)

8/13 (62%)

6/8 (75%)

19/30 (63%)

Extent of expression:

Extent of expression:

Extent of expression:

Extent of expression:

1–5%:4/9 (44%)

1–5%:7/13 (54%)

1–5%:1/8(13%)

1–5%:12/30 (40%)

6–10%:1/9 (11%)

6–10%:0/13 (0%)

6–10%:2/8(25%)

6–10%:3/30 (10%)

11–25%:0/9 (0%)

11–25%:0/13 (0%)

11–25%:2/8(25%)

11–25%:2/30 (7%)

2650%:0/9 (0%)

26–50%:0/13 (0%)

26–50%:0/8(0%)

26–50%:0/30 (0%)

>50%:0/9 (0%)

>50%:1/13 (8%)

>50%:1/8(13%)

>50%:2/30 (7%)

Intermediate-grade (FIGO 2 endometrioid)

5/8 (63%)

3/3 (100%)

9/10 (90%)

17/21 (81%)

Extent of expression:

Extent of expression:

Extent of expression:

Extent of expression:

1–5%:4/8 (50%)

1–5%:1/3 (33%)

1–5%:2/10 (20%)

1–5%:7/21 (33%)

6–10%:0/8 (0%)

6–10%:1/3 (33%)

6–10%:5/10 (50%)

6–10%:6/21 (29%)

11–25%:1/8 (13%)

11–25%:(0%)

11–25%:0/10 (0%)

11–25%:1/21 (5%)

26–50%:0/8 (0%)

26–50%:(0%)

26–50%:2/10 (20%)

26–50%:2/21 (10%)

>50%:0/8 (0%)

>50%:1/3 (33%)

>50%:0/10 (0%)

>50%:1/21 (5%)

High-grade (FIGO 3 endometrioid, dedifferentiated, and carcinosarcoma)

8/8 (100%)

8/9 (89%)

6/7 (86%)

22/24 (92%)

Extent of expression:

Extent of expression:

Extent of expression:

Extent of expression:

1–5%:3/8 (38%)

1–5%:3/9 (33%)

1–5%:2/7 (29%)

1–5%:8/24 (33%)

6–10%:1/8 (13%)

6–10%:4/9 (44%)

6–10%:1/7 (14%)

6–10%:6/24 (25%)

11–25%:1/8 (13%)

11–25%:0/9 (0%)

11–25%:2/7 (29%)

11–25%:3/24 (13%)

26–50%:1/8 (13%)

26–50%:1/9 (11%)

26–50%:1/7 (14%)

26–50%:3/24 (13%)

>50%:2/8 (25%)

>50%:0/9 (0%)

>50%:0/7 (0%)

>50%2/24:(8%)

  1. MMR mismatch repair, MMRd mismatch repair-deficient, nm non-methylated, hm hypermethylated
Back to article page